BRAF and melanoma: The clinical efficacy of selective BRAF inhibitors against BRAFV600E mutant melanoma patients inspired interest in CRC since somatic mutation of this gene occurs in ∼5–10% of colon cancer patients and is associated with poor prognosis [3].